RİTUKSİMAB-VENETOKLAKS PROTOKOLÜ

Kaynaklar:

1- Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol 2017;18:230-240.

2- Kater, A. P., J. F. Seymour, P. Hillmen, et al. 2019. "Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study." J Clin Oncol 37(4):269-277